The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that it had approved ‘Lunsumio (mosunetuzumab),’ which is used to treat follicular lymphoma, on the 3rd of this month.

Lunsumio is used to treat adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Lunsumio is an anti-CD20/CD3 T-cell engaging bispecific antibody that binds to CD3 on the surface of T cells and CD20 on the surface of B cells, and provides a new treatment opportunity for patients with relapsed or refractory follicular lymphoma.

When it binds to CD3, T cells are activated, and when it binds to CD20, it positions B cells nex